MOTIV BTK Randomized Controlled Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 292 participants.

Also called NCT05406622

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 292 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05406622
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Germany (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05406622. Randomized; single masking; primary purpose treatment. Start 2022-06-10 (actual); primary completion 2026-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MOTIV BTK Randomized Controlled Trial
Condition
Critical Limb Ischemia
Intervention (Device)
MOTIV Sirolimus-Eluting Bioresorbable Scaffold
Intervention (Device)
Percutaneous Transluminal Angioplasty (PTA) Device
Lead sponsor
REVA Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05406622
Content hash
b5aa06436d2177e00a99cb3ade3de2dc7b72cf838984d81b86ac6d4fcdfbaad8